<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04453345</url>
  </required_header>
  <id_info>
    <org_study_id>IIT2020003-EC-1</org_study_id>
    <nct_id>NCT04453345</nct_id>
  </id_info>
  <brief_title>TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL</brief_title>
  <official_title>The Efficacy of Thalidomide Plus Prednisone and Methotrexate for the Symptomatic Large Granular Lymphocytic Leukemia - a Prospective Multicenter Clinical Trial From China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Nanchang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin First Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Large granular lymphocytic leukemia (LGLL) is a lymphoproliferative disease, with LGL
      infiltration in peripheral blood and bone marrow, hepatosplenomegaly, and cytopenia. Both
      T-LGLL and CLPD-NK are indolent disease and share similar biology and clinical course, and
      treated under the same strategy. So the investigators put them together as LGLL. The
      investigators used TPM regimen (thalidomide + prednison + methotrexate ) to treat LGLL since
      2013, and 18/20 patients (90%) obtained clinical response, including 80% complete response.
      Adverse events (AE) of grade 3 and above are rare and safe. Therefore, the investigators
      designed this multicenter clinical trial to validate the efficacy of the TPM regimen in
      symptomatic T-LGLL and CLPD-NK.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because LGLL has continuously activated cytotoxic T lymphocytes, immunosuppressive therapy is
      the standard first-line therapy for T-LGLL and CLPD-NK. Previous studies showed that the
      overall response rate (ORR) of first-line oral immunosuppressants ranged from 21% to 85%
      (median: 50%). Both methotrexate and cyclosporine A are LGLL first-line treatment options,
      but the CR rate of methotrexate is only 21%, while the CR rate of CsA is less than 5%. There
      is insufficient evidence for the treatment of LGLL with prednisone and other glucocorticoids,
      but it can reduce RA-related inflammation and increase granulocyte levels. The TPM regimen
      was designed by the investigators. A pilot prospect observation showed that 18/20 (90%)
      patients obtained response, including 80% CR. This study is a prospective multiple center
      clinical trail to evaluate the efficacy of TPM regimen in the treatment of symptomatic LGLL.
      Eligible patients choose the initial treatment plan: thalidomide 50-100mg qn+ prednisone
      0.5-1mg / kg qod +methotrexate 10mg / m2 / week. Four months is one course. Maximum three
      courses will be given if there is a response and thalidomide maintenance will be for another
      year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2013</start_date>
  <completion_date type="Anticipated">May 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 20, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>TPM treatment plan: thalidomide 50-100mg qn + prednisone 0.5-1mg / kg qod +methotrexate 10mg / m2 / week.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response (CR) rate of TPM regimen</measure>
    <time_frame>From date of TPM treatment until the date of complete response, assessed up to 100 months</time_frame>
    <description>Hb&gt; 120g / L，platelet&gt; 100×109 / L，ANC &gt; 1.5×109 / L），ALC&lt; 4×109 / L，peripheral LGL in normal（&lt; 0.5×109 / L）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response (PR)</measure>
    <time_frame>From date of TPM treatment until the date of at least partial response, assessed up to 100 months</time_frame>
    <description>improvement in blood counts (ANC &gt; 0.5 × 10^9/L; HGB increased by &gt;1 g/dL; PLT &gt; 50 × 10^9/L), and the absence of required transfusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>From date of TPM treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>the length of time during and after the treatment of LGLL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>From date of getting response until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>the time from response to progression/death (P/D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>From date of TPM treatment until the date of death from any cause, assessed up to 180 months</time_frame>
    <description>the length of the patients survival time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>T-LGL Leukemia</condition>
  <condition>Clpd-Nk</condition>
  <arm_group>
    <arm_group_label>TPM regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide + prednisone + methotrexate</intervention_name>
    <description>thalidomide 50-100mg daily at bedtime + prednisone 0.5mg/kg qod to 1mg/kg qd + methotrexate 10mg/m2 per week. 4 months one cycle, up to 3 cycles. After get partial remission, thalidomide maintenance will continue up to 2 years.</description>
    <arm_group_label>TPM regimen</arm_group_label>
    <other_name>TPM regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The gender of the patient is not limited, and the age is ≥18 years old;

          2. Must meet diagnostic criteria of T-LGLL or CLPD-NK according to WHO 2016 version;

          3. The patient is treatment naive or received single methotrexate less than 4 weeks and
             without response. If relapsed or refractory patients, the patients must be naive for
             both thalidomide and methotrexate.

          4. With LGLL treatment indications, it mainly includes (meets at least one of the
             following conditions):

               1. ANC &lt;0.5 × 10^9 / L

               2. HGB &lt;100g / L or need red blood cell infusion to maintain

               3. PLT &lt;50 × 10^9 / L

               4. Combining autoimmune diseases that require treatment

               5. symptomatic splenomegaly

               6. Severe B symptoms

               7. Pulmonary hypertension.

          5. ECOG performance status score is 0-2;

          6. The patient's expected survival time is ≥ 6 months.

        Exclusion Criteria:

          1. Unable to understand or follow the research procedure;

          2. Co-occurrent malignant tumors that has to be treated or course the symptom;

          3. Other serious diseases, such as liver, kidney, heart, lung, nerve or metabolic
             diseases, may impede the ability of patients to tolerate methotrexate,
             cyclophosphamide or cyclosporin A;

          4. ALAT / ASAT or alkaline phosphatase&gt; 3 times the normal value;

          5. Creatinine clearance &lt;60ml / min;

          6. Serological evidence of active infection of HIV, hepatitis C or hepatitis B;

          7. Ineffective contraception;

          8. Positive pregnancy test;

          9. Pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lugui Qiu</last_name>
    <role>Study Director</role>
    <affiliation>Blood Disease Hospital, CAMS and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuo Chen</last_name>
    <phone>+86022-23909095</phone>
    <email>chenshuo@ihcams.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiaochuan Li, Dr</last_name>
      <phone>13768411929</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keshu Zhou, Dr</last_name>
      <phone>13674902391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji hopital, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianfeng Zhou, Dr</last_name>
      <phone>13971600192</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongling Peng, Dr</last_name>
      <phone>17612205739</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Li, Dr</last_name>
      <phone>18920526571</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jilin University</name>
      <address>
        <city>Ch'ang-ch'un</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fengyan Jin, Dr</last_name>
      <phone>13844989638</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital, Air Force Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiequn Chen, Dr</last_name>
      <phone>13991907320</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuhua Yi, Dr.</last_name>
      <phone>86-022-23909106</phone>
      <email>yishuhua@ihcams.ac.cn</email>
    </contact>
    <contact_backup>
      <last_name>Lugui Qiu, Dr.</last_name>
      <phone>86-022-23909286</phone>
      <email>qiulg@ihcams.ac.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tianjin First Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qi Deng, Dr</last_name>
      <phone>13516224562</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Dinmohamed AG, Brink M, Visser O, Jongen-Lavrencic M. Population-based analyses among 184 patients diagnosed with large granular lymphocyte leukemia in the Netherlands between 2001 and 2013. Leukemia. 2016 Jun;30(6):1449-51. doi: 10.1038/leu.2016.68. Epub 2016 Apr 8.</citation>
    <PMID>27055870</PMID>
  </reference>
  <reference>
    <citation>Matutes E. Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options. Expert Rev Hematol. 2017 Mar;10(3):251-258. doi: 10.1080/17474086.2017.1284585. Epub 2017 Jan 29. Review.</citation>
    <PMID>28128670</PMID>
  </reference>
  <reference>
    <citation>Moignet A, Lamy T. Latest Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia. Am Soc Clin Oncol Educ Book. 2018 May 23;38:616-625. doi: 10.1200/EDBK_200689. Review.</citation>
    <PMID>30231346</PMID>
  </reference>
  <reference>
    <citation>Zambello R, Teramo A, Gattazzo C, Semenzato G. Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases? Transl Med UniSa. 2014 Feb 4;8:4-11. eCollection 2014 Jan.</citation>
    <PMID>24778993</PMID>
  </reference>
  <reference>
    <citation>Cheon H, Dziewulska KH, Moosic KB, Olson KC, Gru AA, Feith DJ, Loughran TP Jr. Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia. Curr Hematol Malig Rep. 2020 Apr;15(2):103-112. doi: 10.1007/s11899-020-00565-6. Review.</citation>
    <PMID>32062772</PMID>
  </reference>
  <reference>
    <citation>Lamy T, Moignet A, Loughran TP Jr. LGL leukemia: from pathogenesis to treatment. Blood. 2017 Mar 2;129(9):1082-1094. doi: 10.1182/blood-2016-08-692590. Epub 2017 Jan 23. Review.</citation>
    <PMID>28115367</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 24, 2020</study_first_submitted>
  <study_first_submitted_qc>June 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Yi Shuhua</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Large granular lymphocyte leukemia</keyword>
  <keyword>thalidomide</keyword>
  <keyword>methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Large Granular Lymphocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

